TEVA PHARMACEUTICAL INDUSTRIES LTD·4

Mar 19, 8:09 AM ET

Griffin Deborah A 4

4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 19, 2020

Insider Transaction Report

Form 4
Period: 2020-03-17
Griffin Deborah A
Chief Accounting Officer
Transactions
  • Exercise/Conversion

    Ordinary Shares

    2020-03-17+944944 total
  • Sale

    Ordinary Shares

    2020-03-17$7.16/sh944$6,7620 total
  • Exercise/Conversion

    Restricted Share Units

    2020-03-179440 total
    Ordinary Shares (944 underlying)
Footnotes (4)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  • [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.1600 to $7.1850, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F4]Restricted share units were granted on March 17, 2016, with 943 vesting on each of March 17, 2018 and March 17, 2019 and 944 vesting on March 17, 2020.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION